[Recent developments in the treatment of chronic myeloid leukemia].
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001500:BCG Vaccine / Q000627:therapeutic use; D002066:Busulfan / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D008875:Middle Aged; D008927:Mitobronitol / Q000627:therapeutic use; D010198:Pancytopenia / Q000139:chemically induced; D011241:Prednisone / Q000627:therapeutic use; D011658:Pulmonary Fibrosis / Q000139:chemically induced; D013156:Splenectomy; D014182:Transplantation, Autologous; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001500:BCG Vaccine; D014750:Vincristine; D008927:Mitobronitol; D002066:Busulfan; D011241:Prednisone
Neuere Aspekte bei der Behandlung der chronischen myeloischen Leukämie.